Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

127.31 +2.95 (+2.37%)

Official Closing Price Updated: 7:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

52 53 Next >

AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs

October 31, 2025

San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of...

Via TokenRing AI

Topics Artificial Intelligence Supply Chain

AI Revolutionizes Pharma R&D: A New Era of Accelerated Drug Discovery and Personalized Medicine

October 31, 2025

Artificial intelligence (AI) is ushering in a transformative era for pharmaceutical research and development (R&D), fundamentally reshaping how new medicines are discovered, developed, and brought to...

Via TokenRing AI

Topics Artificial Intelligence Intellectual Property

Earnings Scheduled For October 28, 2025 ↗

October 28, 2025

Via Benzinga

Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis ↗

October 27, 2025

Via Stocktwits

What to Expect from Novartis's Earnings ↗

October 27, 2025

Via Benzinga

AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future

October 31, 2025

The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late...

Via TokenRing AI

Topics Animal Testing Artificial Intelligence Economy

Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) ↗

October 31, 2025

Novartis is set to boost its developmental pipeline with this acquisition.

Via The Motley Fool

Here's My Favorite Passive Income Investment ↗

October 31, 2025

International dividend stocks are finally having their moment after years of underperformance, and this single Vanguard fund captures the opportunity with rock-bottom fees.

Via The Motley Fool

Topics ETFs

Is the Market Bullish or Bearish on Novartis AG? ↗

October 29, 2025

Via Benzinga

United Therapeutics Dips As Bread-And-Butter Drug Comes Up Short ↗

October 29, 2025

Shares of United Therapeutics slipped slightly Wednesday on light sales of its bread-and-butter drug, Tyvaso.

Via Investor's Business Daily

Novartis Slips As Generics Champ At Heart-Failure Drug In Mixed Third Quarter ↗

October 28, 2025

Generic competition had a 7 percentage-point negative impact on the company's biggest drug.

Via Investor's Business Daily

Novartis Maintains Outlook Even As Generics Bite Into Profits ↗

October 28, 2025

Novartis Q3 sales rose 8% to $13.91 billion, missing estimates, as Kisqali and Kesimpta drove growth while U.S. generics weighed on results.

Via Benzinga

'Merger Monday' Makes Comeback As US M&A Tops $80 Billion In 24 Hours ↗

October 28, 2025

U.S. companies have struck more than $80 billion worth of deals in the past 24 hours, in the latest sign that mergers and acquisitions (M&A) are picking up after the tariff-induced cool-off earlier...

Via Benzinga

Is It Too Late To Buy Avidity Stock After Novartis Deal? ↗

October 28, 2025

Novartis revealed plans of acquiring Avidity Biosciences Inc. in a $12 billion all-cash transaction. The announcement sent RNA shares soaring roughly 44% on Monday.

Via Talk Markets

Why Dyne Therapeutics Stock Crushed the Market on Monday ↗

October 27, 2025

Biotechs like it are clearly valuable to strategic acquirers.

Via The Motley Fool

Wall Street Soars as Qualcomm Ignites the AI Race ↗

October 27, 2025

Investor optimism drives the S&P 500 to new records while Qualcomm steals the spotlight with an 11% surge after unveiling new AI chips.

Via Chartmill

Topics Artificial Intelligence Stocks

Why Avidity Biosciences Stock Blasted 42% Higher Today ↗

October 27, 2025

If all goes well, the company will be part of a much larger enterprise starting next year.

Via The Motley Fool

Avidity Biosciences Soars After $72 Per Share Novartis Takeover ↗

October 27, 2025

Avidity Biosciences (RNA) to be acquired by Novartis in a $12 billion cash deal. H.C. Wainwright downgrades to Neutral.

Via Benzinga

Qualcomm, Tesla, Intellia Therapeutics, Avidity Biosciences, Dyne Therapeutics: Stocks Making The Biggest Moves Today ↗

October 27, 2025

Qualcomm shares were up more than 11% in Monday’s midday session after the company unveiled two AI accelerator chips.

Via Stocktwits

Topics Artificial Intelligence ETFs Government

Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

October 27, 2025

Via Investor Brand Network

Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

October 27, 2025

EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NYSE:NVS),(NASDAQ:BCAX),(NYSE:PFE) EQNX::TICKER_END

Via FinancialNewsMedia

Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal ↗

October 27, 2025

Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash.

Via Benzinga

Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today ↗

October 27, 2025

Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share.

Via Stocktwits

Stock Market Today: Dow Jones, S&P 500 Futures Climb Ahead Of Busy Week On Wall Street—Novartis, Nucor, Waste Management In Focus ↗

October 27, 2025

U.S. stock futures rose on Monday following Friday’s positive moves. Futures of major benchmark indices were higher.

Via Benzinga

Topics Stocks

Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket ↗

October 27, 2025

Via Benzinga

Inhibrx Stock Soars on Breakthrough Chondrosarcoma Trial Results: A New Dawn for Rare Cancer Treatment

October 24, 2025

San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly...

Via MarketMinute

Jim Cramer: Time To 'Pull The Trigger' On Kratos, A 'Terrific' Stock ↗

October 24, 2025

Kratos secured a $68.3 million deal and a contract through the Defense Department's Industrial Base Analysis and Sustainment Program.

Via Benzinga

AI Revolutionizes Drug Discovery and Personalized Medicine: A New Era of Healthcare

October 22, 2025

The pharmaceutical and biotechnology industries are undergoing a profound transformation, driven by an urgent need for more efficient drug discovery and development processes and the paradigm shift...

Via TokenRing AI

Topics Animal Testing Artificial Intelligence

Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain ↗

October 22, 2025

Novartis' Cosentyx Phase 3 REPLENISH trial for polymyalgia rheumatica met primary and secondary endpoints, showing significant sustained remission.

Via Benzinga

Novartis AG-Sponsored ADR (NYSE:NVS): A Pillar of Dividend Reliability and Financial Health ↗

October 21, 2025

Novartis (NVS) offers a strong 3.35% dividend yield with a history of steady growth, backed by robust profitability and sound financial health for reliable income.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

52 53 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

All News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today